Market
capitalisation:
$9.06m
Shares on issue:
$93.47m
Cash balance:
$8.7m (as at 30 April 2008)
a market cap of 9 million with nearly all of that in cash
Really puts no value on their projects (Funhaler and re-cell)
very tightly held company at the moment, I’ve been trying to get in for a couple of weeks but no one is selling.
ABOUT AVITA MEDICAL LIMITED Avita Medical Limited is a publicly listed biomedical company that is evolving to become a global medical device company. The merger with Visiomed Group Ltd was completed in February 2008 and following the merger the company is now active in the regenerative medicine and respiratory
markets.
Regenerative Medicine
The company develops and distributes tissue-engineered products for the treatment of wounds and other skin defects. Using proprietary tissue culture/collection technology, the company is able to provide innovative treatment solutions derived from the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.
ReCell ®(www.recell.info) is a stand-alone, rapid cell harvesting device that enables surgeons to treat skin defects using the patient’s own cells that are collected during surgery. The surgeon can prepare a small quantity of cells within 30 minutes on site rather than having to send a biopsy to the
laboratory. ReCell ®has been designed for use in a wide variety of plastic, reconstructive and cosmetic procedures. ReCell ®is gaining acceptance in a number of indications including Vitiligo, a common skin pigmentation disease.
ReCell ®is approved for sale in Australia, Brazil, Canada, Chile, Croatia, European Union, Hong Kong, Israel, Japan, Malaysia, New Zealand, Norway, Singapore, South Africa, Switzerland and Turkey. The company is currently focused on securing FDA approval for sale of the product in the
USA.
Respiratory
The company commercialises innovative medical technologies for improved medication delivery and adherence in patients suffering from chronic respiratory diseases. The company manufactures and sells a range of spacers for the paediatric, adolescent and adult market and is the leading provider
of spacers in Australia.
The Funhaler ®incentive asthma spacer has been designed specifically for the paediatric market, incorporating auditory and visual incentives to encourage children to comply with their medication plan. Clinically demonstrated to improve compliance to prescribed medication by 38% and increase
proper inhalation technique in children by 60%. The Funhaler ®is patented, CE marked for the EU, FDA cleared for the US and TGA registered in Australia.
Breath-A-Tech is the leading spacer for adolescents and adults in Australia. The product is effective, compact, easy to use and competitively priced. The Breath-A-Tech hospital-grade spacer can also be autoclaved in the hospital or clinical setting.
Be the first to comment